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Problem Drug procurement and distribution practices are weak in many resource-poor countries, and are a major reason for lack of 
access to medicines. With many countries scaling up antiretroviral therapy (ART), it is vital to avoid interrupted drug supplies, which 
would lead to drug resistance and treatment failure.
Approach Malawi has adapted a model, based on that adopted by the country’s Tuberculosis Control Programme, to allow rational 
ART drug forecasting.
Local setting The model includes a focus on one standardized first-line ART regimen; a “push system” and “ceilings” for first-line 
ART drugs for facilities; use of starter pack and continuation pack kits; quarterly monitoring of patient outcomes and ART drug stocks 
at facility level; provision of a three-month buffer stock of ART drugs at facility level; and use of a procurement and distribution 
system outside central medical stores.
Lessons learned The focus on a single first-line regimen, “ceilings” for first-line ART drugs and quarterly data collections to 
calculate drug needs (for new and follow-up patients, respectively), as well as the use of an independent procurement facility, allow 
drug orders to be made 6–9 months ahead. These measures have so far ensured that there have been no ART drug stock-outs in 
the country.
Bulletin of the World Health Organization 2007;85:152-155.
Une traduction en français de ce résumé figure à la fin de l’article.  Al final del artículo se facilita una traducción al español.
Background
Chloramphenicol and penicillin out of 
stock. For anyone working in sub-Saha-
ran Africa, receiving this statement from 
central medical stores or facility-level 
pharmacies never comes as a surprise. 
A major cause of lack of medicines in 
Africa is weak procurement and distri-
bution practices,1 and this is of major 
concern with many countries now scal-
ing up antiretroviral therapy (ART) to 
thousands of patients.2 ART drug stock-
outs are being documented, and various 
African facilities 3,4 have identified the 
single greatest logistic challenge to ART 
scale-up being that of maintaining drug 
supplies. Stock-outs mean unplanned 
treatment interruptions, which in turn 
cause drug resistance and treatment 
failure. Such adverse events have already 
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been documented from ART clinics in 
sub-Saharan Africa.5
Prevention is better than cure. One 
of the cornerstones of the “DOTS” 
tuberculosis (TB) control strategy is a 
regular, secure supply of anti-TB drugs.6 
Well-run national TB programmes, in-
cluding the programme in Malawi, have 
a structured system of drug forecasting 
and do not experience drug stock-outs. 
Similar principles should be applied to 
ART. First-line ART in many African 
countries consists of a generic fixed-dose 
triple-drug combination, usually taken 
as a single tablet twice a day.7 Resistance 
to first-line therapy means switching to a 
more complicated, expensive, toxic and 
less effective second-line regimen, and 
as far as possible this must be avoided. 
The Ministry of Health in Malawi has 
therefore worked with key partners, 
such as the United Nations Children’s 
Fund (UNICEF), to develop an ART 
procurement model that allows rational 
drug forecasting and uninterrupted drug 
supplies. We describe this model and the 
lessons learned.
Key principles of ART 
procurement and delivery 
in Malawi
Scale-up using one standardized 
first-line ART regimen
The Ministry of Health selected a fixed-
dose generic combination of stavudine 
(d4T), lamivudine (3TC) and nevirapine 
(NVP) as the national first-line regimen, 
and this is the only regimen used by 
most facilities in scaling up ART.8,9 
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Fig. 1. Pre-packed kits of starter packs and continuation packs
Starter pack kit
(based on low burden unit starting 25 new patients on ART per month for three months)
Provides drugs for 75 new patients starting ART for 14 days
150 tins of ART
60 tins of d4T-30 mg/ 3TC (15 tablets – one extra tablet as buffer)
15 tins of d4T-40 mg/ 3TC (15 tablets – one extra tablet as buffer)
60 tins of d4T-30 mg/ 3TC/ NVP (15 tablets – one extra tablet as buffer)
15 tins of d4T-40 mg/ 3TC/ NVP (15 tablets – one extra tablet as buffer)
Continuation pack kit
(based on low burden unit keeping 75 patients on treatment for three months)
Provides drugs for 75 patients to continue on ART for three months, and receive drugs  
every month
225 tins of ART
180 tins of d4T-30 mg/ 3TC/ NVP (60 tablets)
45 tins of d4T-40 mg/ 3TC/ NVP (60 tablets)
ART = antiretroviral therapy; d4T = stavudine; 3TC = lamivudine; NVP = nevirapine.
Note: ART drugs are provided as d4T-30 mg or d4T-40 mg, 3TC-150 mg and NVP-200 mg. The use 
of d4T-30 mg or d4T-40 mg depends on the patient’s weight: those weighing less than 60 kg receive 
d4T-30 mg and those weighing 60 kg or more receive d4T-40 mg. Based on previous experience it was 
estimated that 80% of patients would weigh less than 60 kg and 20% would weigh 60 kg or more.
Alternative first-line regimens are offered 
in case of side-effects and/or specific 
contraindications, and a second-line 
regimen in case of treatment failure. 
Because of limited experience in estimat-
ing demand for, and in the use of, these 
drugs, orders are made only for central 
hospitals and two large district hospitals. 
A system for other facilities to access 
these drugs has been developed and is in 
operation.
A “push system” and “ceilings” 
for first-line ART drugs
From June 2005, there were 60 gov-
ernment and mission health facilities 
delivering first-line ART. Each facility is 
designated as a low burden (starting 25 
new patients per month, n = 30), me-
dium burden (starting 50 new patients 
per month, n = 25), high burden (start-
ing 150 new patients per month, n = 4) 
or very high burden unit (starting 250 
new patients per month, n = 1). This 
classification is based on number of in-
patient beds, area of population served, 
HIV prevalence rate in the population 
(if known) and TB case burden (as a 
proxy for AIDS cases). Drugs are or-
dered for each facility for six months. 
Facilities should not recruit more than 
their expected number of patients, as this 
will endanger drug availability. During 
quarterly supervisions conducted by the 
HIV Unit of the Ministry of Health and 
its partners, facilities are assessed in terms 
of patient recruitment, and those doing 
well are offered the opportunity to raise 
their ceiling and move from a lower to a 
higher category status. Using this system, 
the HIV Unit can calculate the number 
of new patients needing therapy every six 
months. With the current classification, 
17 100 new patients would start ART in 
a six-month period, provided facilities 
worked to full capacity.
A pre-packed kit system 
with “starter packs” and 
“continuation packs”
The development of a starter pack and 
continuation pack kit simplifies drug 
procurement.9 The kit composition is 
shown in Fig. 1. In its first six-month 
period, a low burden facility needs two 
starter pack kits (one for each quarter) 
and three continuation pack kits (one 
for the first three months and two for 
the next three months for those placed 
on treatment in the first quarter and 
those starting treatment in the second 
quarter). Likewise, a medium burden 
unit needs four starter pack and six 
continuation pack kits, while a high 
burden unit needs 12 starter pack and 
18 continuation pack kits.
Quarterly monitoring of patient 
treatment outcomes and ART 
drug stocks
Patients’ outcomes are followed on a 
monthly basis, using ART patient master 
cards.9,10 During quarterly site supervi-
sions, data are collected from each facil-
ity on the number of patients alive and 
on therapy at a set moment in time. This 
is the number who will need continu-
ation therapy, which has to be added 
to the number of new patients starting 
treatment. An ART drug stock check is 
also made in the pharmacy to record the 
number of different bottles of first-line, 
alternative first-line and second-line 
therapy on the shelves.
Buffer stocks of first-line ART
Buffer stocks are important to guard 
against unforeseen events. Each facility 
is given a three-month buffer stock, the 
mechanism being that the six-month 
drug orders come in three months early 
on a regular basis.
Forecasting first-line ART drug 
requirements for each facility
An example of how to forecast first-line 
ART drug needs at a low burden facility 
is provided in Table 1. This drug order 
was prepared in early October 2005 
for the period July to December 2006, 
with the arrival of drugs planned three 
months early in April 2006. For new 
patients starting ART between July and 
December 2006, the calculations are 
straightforward: two starter pack and 
three continuation pack kits. The calcu-
lation of drugs needed for six months for 
patients already on ART and predicted 
to be alive in July 2006 is shown in 
the table. Several calculations and as-
sumptions are required which include: 
number of patients alive and on ART in 
October 2005; number of new patients 
starting ART between October 2005 and 
July 2006; estimated number of patients 
who will die, default, stop treatment or 
transfer-out during this period (based 
on quarterly monitoring reports);9,10 
drugs arriving in country for the facility 
between October 2005 and July 2006; 
and drug stocks in October 2005.
Use of a parallel procurement 
and distribution system for ART
A World Bank assessment of the gov-
ernment central medical stores in 2002 
strongly advised, for various reasons, that 
another institution be used for procure-
ment of HIV/AIDS and ART drugs 
with funding from the Global Fund to 
Fight AIDS, Tuberculosis and Malaria. 
UNICEF was chosen and is responsible 
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Table1. Forecasting first-line antiretroviral therapy (ART) drug requirements
Patients alive and needing ART by 1 July 2006 Number of patients
A. Patients alive and on ART at end of September 2005 (156) and predicted to be alive and on ART by 1 July 
2006 — assuming a 10% attrition rate over this period
140
B. New patients starting ART between October 2005 and June 2006 (225) and predicted to be alive and on ART 
by 1 July 2006 — assuming a 10% attrition rate over this period
203
Patients alive and needing ART by 1 July 2006 (A+B) 343
Bottles (60 tablets) of d4T-3TC-NVP  in stock by 1 July 2006 Number of bottles
Bottles of d4T-3TC-NVP consumed by patients in category A 1260
Bottles of d4T-3TC-NVP consumed by patients in category B 1012
C. Total bottles of d4T-3TC-NVP consumed by patients in categories A and B by 1 July 2006 2272
Bottles of d4T-3TC-NVP in stock at end of September 2005 1730
Bottles of d4T-3TC-NVP arriving in October–November 2005 2000
D. Total bottles of d4T-3TC-NVP in stock or arriving before next drug order in April 2006 3730
Bottles of d4T-3TC-NVP in stock by 1 July 2006 (D-C) 1458
Bottles (60 tablets) of d4T-3TC-NVP to procure July–Dec 2006 Number of bottles
E. Bottles of d4T-3TC-NVP for 343 patients for 6 months — assuming no attrition during this period 2058
F. Bottles of d4T-3TC-NVP already in stock on 1 July 2006 1458
Bottles of d4T-3TC-NVP to procure July–Dec 2006 (E-F) 600
d4T = stavudine; 3TC = lamivudine; NVP = nevirapine.
Note: This is an example of a drug procurement order, put together in October 2005, for a low burden unit. This six-month order was for continuation drugs for 
patients predicted to be alive and on ART on 1 July 2006, and translated into three continuation pack kits.
for procuring and distributing ART 
drugs in Malawi. WHO pre-qualified 
drugs are procured mainly from CIPLA, 
India, packaged into the quantities 
determined for each facility, shipped to 
Malawi and immediately distributed to 
the facilities.
Evaluation and lessons 
learned
This drug procurement model has 
worked well so far. Drug stocks are 
monitored during quarterly site super-
visions, and there have been no drug 
stock-outs as of 30 June 2006. There 
have been three important lessons 
learned in this process (Box 1). First, a 
focus on a single first-line regimen, rather 
than having several different regimens 
to choose from, simplifies the process 
of drug ordering, particularly as patient 
numbers continue to increase. Second, 
using “ceilings” for first-line ART drugs 
and obtaining quarterly data on patient 
outcomes and drug stocks provide a 
rational basis for calculating ART drug 
needs for new and follow-up patients, 
respectively. Quarterly supervisions also 
allow site-specific distribution problems 
to be tackled, and drugs can be moved 
between facilities that under-perform or 
over-perform. Third, once government 
procurement facilities had been judged 
to be weak, taking the decision to use 
another procurement agency has allowed 
scale-up to proceed smoothly, although 
eventually ways will have to be found 
to integrate drug supplies back into 
national procurement systems. Time will 
Box 1. Lessons learned
• A focus on a single first-line regimen simplifies the process of drug ordering.
• The use of “ceilings” for first-line ART drugs and quarterly data on patient outcomes and 
drug stocks allow rational calculations of ART drug needs for new and follow-up patients, 
respectively.
• The use of another procurement agency, if the government facility is judged to be weak, 
allows ART scale-up to proceed with confidence.
tell whether Malawi’s model will cope 
with increasing numbers of ART facili-
ties and patients starting treatment.  O
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Résumé
Garantir un approvisionnement ininterrompu en médicaments antirétroviraux dans un pays à ressources 
limitées : exemple du Malawi
Problème Dans beaucoup de pays à ressources limitées, il n’existe 
guère de procédures d’achat et de distribution des médicaments 
solidement organisées, ce qui est l’une des raisons majeures du 
manque d’accès aux médicaments. De nombreux pays ayant 
entrepris d’étendre l’application des traitements antirétroviraux 
(ART), il importe d’éviter toute interruption de l’approvisionnement 
en médicaments, susceptible d’entraîner l’apparition d’une 
résistance médicamenteuse et des échecs thérapeutiques.
Démarche suivie Le Malawi a adapté le modèle utilisé par le 
Programme national de lutte contre la tuberculose pour prévoir 
les besoins nationaux en antirétroviraux.
Contexte local Ce modèle fait appel à un schéma thérapeutique 
ART de première intention unique et standardisé, à un système 
de type «pulsion» et à des «plafonds» pour les médicaments 
antirétroviraux de première intention destinés aux établissements 
de santé ; à l’association d’un kit de mise en route du traitement 
et de kits pour phase d’entretien, à un suivi sur trois mois des 
résultats obtenus chez les patients et des stocks d’antirétroviraux 
au niveau des établissements, au maintien d’un stock tampon 
pour 3 mois dans les établissements, ainsi qu’à un système 
d’achat et de distribution indépendant des magasins centraux de 
médicaments.
Enseignements tirés Grâce à l’utilisation majoritaire d’un 
schéma thérapeutique de première intention unique et de 
«plafonds» pour les ART de première intention, à la collecte 
trimestrielle de données pour calculer les besoins en médicaments 
(pour les nouveaux patients et ceux en cours de traitement 
respectivement) et au recours à une unité d’achat indépendante, 
il est possible d’établir les commandes de médicaments 6 à 9 mois 
à l’avance. Ces mesures ont permis jusqu’à présent d’éviter toute 
rupture de stocks d’antirétroviraux dans le pays.
Resumen
Garantizar el suministro ininterrumpido de antirretrovirales en los entornos con pocos recursos: el 
ejemplo de Malawi
Problema Las prácticas de adquisición y distribución de los 
medicamentos son deficientes en muchos países de escasos 
recursos, y explican en buena parte los problemas de falta 
de acceso a los fármacos. Paralelamente a la expansión del 
tratamiento antirretroviral (TAR) llevada a cabo en numerosos 
países, es fundamental evitar cualquier interrupción del suministro 
de medicamentos, circunstancia que conduce a la aparición de 
farmacorresistencia y al fracaso terapéutico.
Métodos Malawi ha adaptado un modelo, basado en el empleado 
por el Programa de Lucha contra la Tuberculosis del país, que 
permite hacer proyecciones racionales de las necesidades de 
antirretrovirales.
Contexto local El modelo incluye la focalización en un régimen 
normalizado de TAR de primera línea; un «sistema impulsor» 
y «techos» de medicamentos antirretrovirales de primera línea 
para los centros asistenciales; el uso de un kit inicial y de kits de 
mantenimiento; el monitoreo trimestral de la evolución de los 
pacientes y de las reservas de antirretrovirales en los centros; 
la provisión de una reserva de estabilización de tres meses de 
antirretrovirales en los centros; y el uso de un sistema de adquisición 
y distribución independiente de los almacenes médicos centrales.
Experiencia adquirida La focalización en un solo régimen de 
primera línea, los «techos» para los antirretrovirales de primera 
línea y la recogida trimestral de datos para calcular las necesidades 
de medicamentos (para pacientes nuevos y de seguimiento, 
respectivamente), así como el recurso a un centro de adquisiciones 
independiente, permite hacer los pedidos de medicamentos con 
6-9 meses de antelación. Gracias a esas medidas, hasta ahora no 
se ha producido ninguna situación de desabastecimiento de TAR 
en el país.
صخلم
 عقاولما في ةيرقهقلا تاسويرفلل ةداضلما ةيودلأا نم ةلصاوتلما تادادملإا نماض
يولاام نم لاثم :دراولما ةيرقفلا
 نادلبلا نم يرثكلا في فعضلا نم عيزوتلاو ءاشرلا تاسرمام نياعت :ةلكشلما
 يروضرلا نمو ،ةيودلأا ةحاتإ  نادقفل سييئرلا  ببسلا وهو ،دراولما ةيرقفلا
 ةيرقهقلا  تاسويرفلل  ةداضلما  ةجلاعلماب  ضهنت  يتلا  نادلبلا  نم  يرثكلا  في
 لىإو  ةيودلأا  ةمواقم  لىإ  يدؤي  مام  وهف  ،ةيودلأا  دادمإ  في  عطقتلا  بنجت
.ةجلاعلما لشف
 جمانبرلا  هانبت  يذلا  جذومنلا  لىع  زكتري  ًاجذونم  يولاام  تل َّدع  :بولسلأا
 تاسويرفلل ةداضلما ةديشرلا ةيودلأاب ؤبنتلاب حماسلل ،لسلا ةحفاكلم ينطولا
.ةيرقهقلا
 يرايعم  يجلاع  ماظن  لىع  زيكترلا  لىع  جذومنلا  لمتشي  :ليحلما  عقولما
 ،»عفد ماظن«و ،ةيرقهقلا  تاسويرفلل  ةداضلما  ةيودلأل  يماملأا  طخلل  دحاو
 مادختساو  ،ةيرقهقلا  تاسويرفلل  ةداضلما  لولأا  طخلا  ةيودلأ  »فوقس«و
 لئاصحلل  روهش  ةثلاث  مودي  دصرو  ،ةموادلما  تاوبعو  ةيادبلا  ةوبعل  دئاتع
 لىع  ةيرقهقلا  تاسويرفلل  ةداضلما  ةيودلأا  نم  تانوزخمللو  ضىرلما  ىدل
 روهش ةثلاثل يفكي ئراد يطايتحا نوزخم ميدقتو ،يحصلا قفرلما ىوتسم
 عيزوتلاو ءاشرلا ماظن مادختساو ،ةيرقهقلا  تاسويرفلل  ةداضلما ةيودلأا نم
.ةيزكرلما ةيبطلا نزاخلما جراخ
 طخلل فوقسو ،لولأا طخلل ديحو ماظن لىع زيكترلا نإ :ةدافتسلما سوردلا
 ةثلاث لك تايطعلما عمجو ،ةيرقهقلا تاسويرفلل ةداضلما ةيودلأا نم لولأا
 ةعباتلمو  ددجلا  ضىرلما  نم  لكل  ةيودلأا  نم  تاجايتحلاا  باسحل  روهش
 فُّرعتلاب حمسي كلذ لك ،ءاشرلل ةلقتسم قفارم مادختساو ،ىمادقلا ضىرلما
 هذه نمضتو .ةيلاتلا  ةعستلا  وأ  ةتسلا  رهشلأل ةيودلأل ةقبسم تابلط لىع
 تاسويرفلل ةداضلما ةيودلأا نم نزاخملل دافن تلااح ثودح مدع تاءارجلإا
.دلبلا في ةيرقهقلا
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